2 Healthcare Stocks That Could Soar Over the Next 5 Years

Moderna shares are up ~73% YTD as its personalized cancer vaccine mRNA-4157 published five-year phase 2 follow-up showing a significant reduction in recurrence/death versus Keytruda alone; the company is also pursuing a U.S. mRNA flu vaccine approval. Abivax's obefazimod met the phase 3 primary endpoint for clinical remission in moderate-to-severe ulcerative colitis (with ~47.3% of trial patients previously unsuccessfully treated, including JAK inhibitors) and maintenance data are expected in Q2. Both stories offer sizeable upside if approvals/readouts are positive but remain highly binary and susceptible to clinical/regulatory setbacks, making them suitable only for risk-tolerant allocations.

Analysis

Winners extend beyond the two tickers: a durable clinical win for Moderna's personalized oncology program materially increases demand for rapid NGS-based tumor profiling and small-batch LNP/CDMO capacity. Expect beneficiaries to be niche diagnostics and CDMOs with flexible, quick-turn capabilities rather than the largest integrated manufacturers — a regime shift from high-volume vaccine supply to high-mix, low-volume personalized runs. For Abivax, a clean safety profile versus JAKs would not only pressure JAK market share but also force payers to re-evaluate step-therapy protocols, creating downstream pressure on JAK pricing and formulary position for incumbents (e.g., large immunology franchises). This dynamic makes mid-sized immunology specialists potential acquisition predators if obefazimod demonstrates durable maintenance benefit in previously treated patients.

Timeline and tail risks are asymmetric and binary. Abivax presents a single near-term catalyst (maintenance readout in Q2) that can rerate the name >2x on a clean signal or halve it on negative/ambiguous data; position sizing must reflect ~>40% downside tail on failure. Moderna’s oncology path is multi-year: meaningful commercial and margin realization hinges on multiple phase 3 readouts, companion diagnostic rollout, and payer acceptance, exposing the stock to valuation compression if cadence slips — but success scales revenue pathways across many tumor types. Regulatory and reimbursement friction, manufacturing bottlenecks for individualized products, and headline-driven sentiment shifts are the primary reversal mechanisms for both names.

Practical trade framing: treat Abivax as a binary event trade sized for limited loss and high theta sensitivity; implant a stop or option-based defined-loss structure. For Moderna, prefer time-levered, limited-capital bullish exposure (LEAP call spreads or buy-write strategies) that capture multi-year upside while protecting against mean reversion from rich sentiment. A defensive pair trade (long ABVX / short a large JAK incumbent or hedged biotech basket) can isolate product-event upside while partially funding premium for options exposure. Monitor diagnostics/CDMO revenue surprises and large pharma M&A chatter as early secondary signals of de-risking/commercial interest.

Key Decisions for Investors

• Initiate a tactical long on ABVX via Sep-2026 call spread (buy ATM call, sell a higher strike) sized to 0.25% NAV — asymmetry: potential >2x payoff if Q2 maintenance readout is positive; defined max loss = premium paid (~100% downside to premium).
• Establish a core Moderna LEAP bullish position via Jan-2029 call spread (buy lower strike, sell higher strike) at 0.75% NAV to capture multi-year oncology optionality while capping capital at premium; target 2.5-4x on successful program readouts/commercial uptake, downside limited to premium if timelines slip.
• Pair trade: long ABVX (0.25% NAV) / short ABBV (or another large JAK incumbent, equal notional delta-adjusted) to express displacement risk; this reduces market beta and monetizes potential share-shift while limiting exposure to broad biotech sentiment moves.
• Event risk management: for ABVX, place a hard 40-60% stop on equity exposure or use options to cap downside; for MRNA, sell 3–6 month covered calls on a tranche (30–40% of position) to fund LEAP premium and defend against 6–12 month mean reversion.
• Watch-list triggers: upgrade size on ABVX only after a positive Q2 maintenance readout plus corroborating safety signal across secondary endpoints; for MRNA, increase exposure only after a positive randomized P3 oncology readout or a material CDMO partnership that scales personalized manufacturing capacity.